Equibles does not estimate personal net worth.
Get an email with a short summary when Abeona Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get ABEO alertsEric Crombez is recorded as Board Member at Abeona Therapeutics Inc. (ABEO). The newest filing on record that lists Eric Crombez as Board Member at Abeona Therapeutics Inc. (ABEO) is dated April 27, 2026. Abeona Therapeutics Inc. reported in an 8-K filed August 14, 2024 that Eric Crombez was appointed member of the Board, effective August 12, 2024. The proxy statement of Ultragenyx Pharmaceutical Inc. reports total compensation of $4,002,173 for Eric Crombez in fiscal 2025, including a base salary of $630,231. Disclosed compensation is on record for 2 fiscal years. Eric Crombez has spoken on 3 earnings calls and 3 other investor events across 1 company, most recently for Ultragenyx Pharmaceutical Inc. on November 3, 2026. Ultragenyx Pharmaceutical Inc. is classified in the Biotechnology industry within the Healthcare sector. Abeona Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ultragenyx Pharmaceutical Inc. includes Emil D. Kakkis (CEO and Board Member), Emil Kakkis (CEO and Board Member), Howard Horn (CFO) and 7 others.
“appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.”
“Yeah, so we haven't disclosed exactly how we powered that study, but we are looking for complete responders, those patients who are able to come completely off of alternate pathway medication and diet, responders, those who are able to come at least 50% down from there, and looking at the combination of those in a…”
“FAYUV is indicated for the treatment of neurologic manifestations of muco polysaccharidosis type 3A or San Filippo syndrome type A in pediatric patients with preserved neurodevelopmental function.”
“The approval of GenGlycose fulfills our commitment to provide the first therapy that directly targets the root cause of GST1A. The reduced reliance on corn starch demonstrates this liver-directed gene therapy's capability to deliver the necessary transgene to enable patients' livers to break down glycogen and to…”
“So just very briefly, founded in 2010, public in 2014, founded by our current CEO, Amal Kakis, with a real focus on rare disease and focusing on patients and diseases where there still remains a high level of unmet medical need.”
“The Phase 3 studies do have a very high retention rate, including patients electing to continue in a long-term extension study.”
Start not stated–present
Last confirmed April 27, 2026
Proxy statement
Start not stated–present
Last confirmed March 27, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Medical Officer and Executive Vice President | $630,231 | $4,002,173 |
| 2024 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Medical Officer and Executive Vice President | $591,846 | $4,298,223 |
